74 search results for: symposium

Missing material
Content temporarily unavailable
ADVENT at CEORL-HNS 2026

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

Missing material
Content temporarily unavailable
CEORL-HNS 2026 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

Missing material
Content temporarily unavailable
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.

Missing material
Content temporarily unavailable
ADVENT at IRS-ISIAN | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

Join Profs. Shigeharu Fujieda, Peter Hellings, and Eugenio De Corso for an educational symposium on the evolving understanding of disease control and clinical remission in CRSwNP.

Missing material
Content temporarily unavailable
ADVENT at UEG Week 2024

Join ADVENT at UEG Week 2024 (United European Gastroenterology) for an educational symposium on type 2 inflammation in EoE. Visit Booth #25 to learn more about ADVENT.

Missing material
Content temporarily unavailable
ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.

Missing material
Content temporarily unavailable
Current and Emerging Therapeutic Options for Children With Atopic Dermatitis

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang reviews the current and emerging treatment options for children with AD uncontrolled with topical therapy, including a summary of recent long-term data for advanced systemic therapies

Missing material
Content temporarily unavailable
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.

Missing material
Content temporarily unavailable
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime

Join ADVENT faculty members Len Bacharier, Antonella Cianferoni, and Andre Moreira for an educational symposium highlighting type 2 inflammation and its shared and distinct roles in multiple chronic pediatric diseases.

Missing material
Content temporarily unavailable
Atopic Dermatitis in Children: Not Just a Skin Disease

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the multidimensional and cumulative disease burden of AD and its associated comorbidities in children. Dr Boguniewicz also highlights the burden experienced by caregivers of children with AD

Missing material
Content temporarily unavailable
Real-World Effectiveness of Advanced Systemic Treatments in AD

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Marjolein de-Bruin Weller discusses the latest real-world data on the effects of advanced systemic treatments in patients with AD.

Missing material
Content temporarily unavailable
Type 2 Inflammation and Its Role in Atopic Dermatitis

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert reviews the epidemiology, clinical presentation, and differential diagnoses of AD in children, as well as the inflammatory processes driven by type 2 cytokines that lead to AD and its atopic comorbidities